The capital market consequences of stock market liberalisation: Evidence from Mainland‐Hong Kong Stock Connect Programs in China
Accounting & Finance · 2024-12 · 64 (4) · 3275-3299
DOI: 10.1111/acfi.13251 ↗Kurz gefasst
Fachartikel in der Zeitschrift Accounting & Finance, online erschienen am 02.04.2024. Verfasst von Renhui Fu und 2 weiteren Autor:innen. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 67 Literaturangaben.
Abstract (Originalsprache)
We analyse the capital market consequences of stock market liberalisation in a quasi‐natural experiment setting, where Mainland‐Hong Kong Stock Connect Programs allow foreign investors to trade in the Chinese stock market. Utilising difference‐in‐differences estimations, we observe improved stock liquidity, driven by direct liquidity provision and indirect signals to domestic investors. Particularly notable are the effects on eligible stocks without previous exposure to foreign investors, characterised by high corporate transparency and investor protection. The resulting liquidity enhancements reduce equity costs, ultimately elevating firm value. In short, our study highlights the positive influence of stock market liberalisation on the capital market.
Zitieren
APA
Fu, R., Gao, F., & Zhao, Y. (2024). The capital market consequences of stock market liberalisation: Evidence from Mainland‐Hong Kong Stock Connect Programs in China. Accounting & Finance, 64(4), 3275-3299. https://doi.org/10.1111/acfi.13251
Vancouver
Fu R, Gao F, Zhao Y. The capital market consequences of stock market liberalisation: Evidence from Mainland‐Hong Kong Stock Connect Programs in China. Accounting & Finance. 2024;64(4):3275-3299. doi:10.1111/acfi.13251
BibTeX
@article{Fu2024,
author = {Fu, Renhui and Gao, Fang and Zhao, Yi},
title = {The capital market consequences of stock market liberalisation: Evidence from Mainland‐Hong Kong Stock Connect Programs in China},
journal = {Accounting & Finance},
year = {2024},
volume = {64},
number = {4},
pages = {3275--3299},
doi = {10.1111/acfi.13251}
}
EUVIMED